Enzon Pharmaceuticals Inc
ENZN
Get informed when a big investor buys or sells
+ FollowMarket Cap$31.14M
Close$
$0.63
86.5% downside
Current Fair Value
86.5% downsideOvervalued by 86.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $31.14 Million |
|---|---|
| Enterprise Value | $98.14 Million |
| Dividend Yield | $18.00 (-) |
| Earnings per Share | $-7.46 |
| Beta | -0.04 |
| Outstanding Shares | 14,331,620 |
Return
| Return on Equity | -7.31% |
|---|---|
| Return on Assets | -3.21% |
| Return on Invested Capital | -2.08% |
Valuation & Multiples
| P/E Ratio | -0.91 |
|---|---|
| PEG | -0.22 |
| Price to Sales | 0.39 |
| Price to Book Ratio | 0.36 |
| Enterprise Value to Revenue | 0.56 |
| Enterprise Value to EBIT | -15.69 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.76 |
| Debt to Equity | 0.4 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 3, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Enzon Pharmaceuticals Inc
CEO: Andrew Rackear Enzon Pharmaceuticals, Inc is a pharmaceutical company engaged in developing therapeutics to patients whose needs are unmet. Its headquarters is now in Piscataway, New Jersey. The company is a publicly traded company on NASDAQ under the ...